The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections
Abstract
The emergence of multidrug-resistant gram-negative bacteria and the lack of new antibiotics to combat them have led to the revival of polymyxins, an old class of cationic, cyclic polypeptide antibiotics. Polymyxin B and polymyxin E (colistin) are the 2 polymyxins used in clinical practice. Most of the reintroduction of polymyxins during the last few years is related to colistin. The polymyxins are active against selected gram-negative bacteria, including Acinetobacter species, Pseudomonas aeruginosa, Klebsiella species, and Enterobacter species. These drugs have been used extensively worldwide for decades for local use. However, parenteral use of these drugs was abandoned approximately 20 years ago in most countries, except for treatment of patients with cystic fibrosis, because of reports of common and serious nephrotoxicity and neurotoxicity. Recent studies of patients who received intravenous polymyxins for the treatment of serious P. aeruginosa and Acinetobacter baumannii infections of various types, including pneumonia, bacteremia, and urinary tract infections, have led to the conclusion that these antibiotics have acceptable effectiveness and considerably less toxicity than was reported in old studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Guide to the Natural History of Freshwater Lake Bacteria
Newton, R. J., Jones, S. E., Eiler, A., McMahon, K. D., & Bertilsson, S. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00028-10 · Cited by 1,585
British Journal of Pharmacology
(2010) · British Journal of Pharmacology · doi:10.1111/(issn)1476-5381 · Cited by 920
Polymyxin and Related Peptide Antibiotics
Storm, D. R., Rosenthal, K. S., & Swanson, P. E. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.003451 · Cited by 759
Gunn, J. S., Lim, K. B., Krueger, J., Kim, K., Guo, L., Hackett, M., & Miller, S. I. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.00757.x · Cited by 655
Levin, A. S., Barone, A. A., Penço, J., Santos, M. V., Marinho, I. S., Arruda, E. A. G., Manrique, E. I., & Costa, S. F. (1999) · Clinical Infectious Diseases · doi:10.1086/514732 · Cited by 612
The peptide antibiotics of Bacillus: chemistry, biogenesis, and possible functions
Katz, E., & Demain, A. L. (1977) · Bacteriological Reviews · doi:10.1128/br.41.2.449-474.1977 · Cited by 540
Garnacho‐Montero, J., Ortiz‐Leyba, C., Jimenez‐Jimenez, F. J., Barrero‐Almodovar, A. E., Garcia‐Garmendia, J. L., Bernabeu‐WittelI, M., Gallego‐Lara, S. L., & Madrazo‐Osuna, J. (2003) · Clinical Infectious Diseases · doi:10.1086/374337 · Cited by 470
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS: 2007 INSTRUCTIONS TO AUTHORS
(2007) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00038-06 · Cited by 420
Gales, A. C., Reis, A. O., & Jones, R. N. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.183-190.2001 · Cited by 382
THE PROPERTIES AND MODE OF ACTION OF THE POLYMYXINS
Newton, B. A. (1956) · Bacteriological Reviews · doi:10.1128/br.20.1.14-27.1956 · Cited by 349
Cited by
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Dellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510393 · Cited by 3,362
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents
Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00194 · Cited by 1,927
Molecular Mechanisms of Antibacterial Multidrug Resistance
Alekshun, M. N., & Levy, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.03.004 · Cited by 1,647
Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence
Moradali, M. F., Ghods, S., & Rehm, B. H. A. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00039 · Cited by 1,537
Poirel, L., Jayol, A., & Nordmann, P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-16 · Cited by 1,447
Clinical relevance of the ESKAPE pathogens
Pendleton, J. N., Gorman, S. P., & Gilmore, B. F. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.12 · Cited by 1,423
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance
Navon-Venezia, S., Kondratyeva, K., & Carattoli, A. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux013 · Cited by 1,286
Antimicrobial Resistance: a One Health Perspective
McEwen, S. A., & Collignon, P. J. (2018) · Microbiology Spectrum · doi:10.1128/microbiolspec.arba-0009-2017 · Cited by 1,199
Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D., Scheld, M., & Bartlett, J. G. (2006) · Clinical Infectious Diseases · doi:10.1086/499819 · Cited by 1,104
Efflux-mediated antimicrobial resistance
Poole, K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki171 · Cited by 1,082
Phage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 998
Maragakis, L. L., & Perl, T. M. (2008) · Clinical Infectious Diseases · doi:10.1086/529198 · Cited by 969
The negative impact of antibiotic resistance
Friedman, N. D., Temkin, E., & Carmeli, Y. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.12.002 · Cited by 870
Pharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Falagas, M. E., & Kasiakou, S. K. (2006) · Critical Care · doi:10.1186/cc3995 · Cited by 828
Self-citationColistin and its role in the Era of antibiotic resistance: an extended review (2000–2019)
El-Sayed Ahmed, M. A. E.-G., Zhong, L.-L., Shen, C., Yang, Y., Doi, Y., & Tian, G.-B. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1754133 · Cited by 761
Silver Enhances Antibiotic Activity Against Gram-Negative Bacteria
Morones-Ramirez, J. R., Winkler, J. A., Spina, C. S., & Collins, J. J. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006276 · Cited by 756
Mechanisms and consequences of bacterial resistance to antimicrobial peptides
Andersson, D. I., Hughes, D., & Kubicek-Sutherland, J. Z. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.04.002 · Cited by 715
Garonzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., & Nation, R. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01733-10 · Cited by 696
Ageitos, J. M., Sánchez-Pérez, A., Calo-Mata, P., & Villa, T. G. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.018 · Cited by 614
Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli
Giske, C. G., Monnet, D. L., Cars, O., & Carmeli, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01169-07 · Cited by 610
Antimicrobial peptides: an overview of a promising class of therapeutics
Giuliani, A., Pirri, G., & Nicoletto, S. (2007) · Open Life Sciences · doi:10.2478/s11535-007-0010-5 · Cited by 606
The Characteristic of Virulence, Biofilm and Antibiotic Resistance of Klebsiella pneumoniae
Wang, G., Zhao, G., Chao, X., Xie, L., & Wang, H. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17176278 · Cited by 591
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium
Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., et al. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01681.x · Cited by 585
Colistin: an update on the antibiotic of the 21st century
Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M., & Rolain, J.-M. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.78 · Cited by 581
Klebsiella pneumoniae: an increasing threat to public health
Effah, C. Y., Sun, T., Liu, S., & Wu, Y. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-019-0343-8 · Cited by 558
Landman, D., Georgescu, C., Martin, D. A., & Quale, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00006-08 · Cited by 565
Enterobacter cloacae Complex: Clinical Impact and Emerging Antibiotic Resistance
Mezzatesta, M. L., Gona, F., & Stefani, S. (2012) · Future Microbiology · doi:10.2217/fmb.12.61 · Cited by 562
Cai, Y., Chai, D., Wang, R., Liang, B., & Bai, N. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks084 · Cited by 557
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00103-06 · Cited by 548
Alteration of Zeta potential and membrane permeability in bacteria: a study with cationic agents
Halder, S., Yadav, K. K., Sarkar, R., Mukherjee, S., Saha, P., Haldar, S., Karmakar, S., & Sen, T. (2015) · SpringerPlus · doi:10.1186/s40064-015-1476-7 · Cited by 545
Van Hamme, J. D., Singh, A., & Ward, O. P. (2006) · Biotechnology Advances · doi:10.1016/j.biotechadv.2006.08.001 · Cited by 474
Polymyxin: Alternative Mechanisms of Action and Resistance
Trimble, M. J., Mlynárčik, P., Kolář, M., & Hancock, R. E. W. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025288 · Cited by 454
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
Karageorgopoulos, D. E., & Falagas, M. E. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70279-2 · Cited by 446
Self-citationTowards Understanding MCR-like Colistin Resistance
Sun, J., Zhang, H., Liu, Y.-H., & Feng, Y. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.02.006 · Cited by 446
Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing
Lim, L. M., Ly, N., Anderson, D., Yang, J. C., Macander, L., Jarkowski, A., Forrest, A., Bulitta, J. B., & Tsuji, B. T. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.12.1279 · Cited by 444
Nation, R. L., & Li, J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328332e672 · Cited by 443
Sandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., Behle, T. F., Bordinhão, R. C., Wang, J., Forrest, A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit334 · Cited by 430
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Rescuing the Last-Line Polymyxins: Achievements and Challenges
Nang, S. C., Azad, M. A. K., Velkov, T., Zhou, Q. (., & Li, J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000020 · Cited by 421
Chang, Y.-T., Lin, C.-Y., Chen, Y.-H., & Hsueh, P.-R. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00893 · Cited by 419
Molecular mechanisms of polymyxin resistance: knowns and unknowns
Baron, S., Hadjadj, L., Rolain, J.-M., & Olaitan, A. O. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.06.023 · Cited by 414
One Health—Its Importance in Helping to Better Control Antimicrobial Resistance
Collignon, P. J., & McEwen, S. A. (2019) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed4010022 · Cited by 407
Kempf, M., & Rolain, J.-M. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.10.004 · Cited by 389
Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance
Gordon, N. C., & Wareham, D. W. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.024 · Cited by 378
Thapa, R. K., Diep, D. B., & Tønnesen, H. H. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.12.025 · Cited by 378
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 372
The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace
Roca, I., Espinal, P., Vila-Farrés, X., & Vila, J. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00148 · Cited by 363
Treatment of Acinetobacter Infections
Fishbain, J., & Peleg, A. Y. (2010) · Clinical Infectious Diseases · doi:10.1086/653120 · Cited by 358
Tackling Threats and Future Problems of Multidrug-Resistant Bacteria
Medina, E., & Pieper, D. H. (2016) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2016_492 · Cited by 356
Nation, R. L., Li, J., Cars, O., Couet, W., Dudley, M. N., Kaye, K. S., Mouton, J. W., Paterson, D. L., Tam, V. H., Theuretzbacher, U., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70850-3 · Cited by 354
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes
van Duin, D., Kaye, K. S., Neuner, E. A., & Bonomo, R. A. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.11.009 · Cited by 352
Falagas, M. E., Lourida, P., Poulikakos, P., Rafailidis, P. I., & Tansarli, G. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01222-13 · Cited by 351
Self-citationKarampatakis, T., Tsergouli, K., & Behzadi, P. (2023) · Antibiotics · doi:10.3390/antibiotics12020234 · Cited by 339
Billings, N., Ramirez Millan, M., Caldara, M., Rusconi, R., Tarasova, Y., Stocker, R., & Ribbeck, K. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003526 · Cited by 326
Molecular mechanisms related to colistin resistance in Enterobacteriaceae
Aghapour, Z., Gholizadeh, P., Ganbarov, K., bialvaei, A. Z., Mahmood, S. S., Tanomand, A., Yousefi, M., Asgharzadeh, M., Yousefi, B., & Samadi Kafil, H. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s199844 · Cited by 320
Transferable resistance to colistin: a new but old threat: Table 1.
Schwarz, S., & Johnson, A. P. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw274 · Cited by 314
Gales, A. C., Jones, R. N., & Sader, H. S. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01351.x · Cited by 302
Resistance to polymyxins: Mechanisms, frequency and treatment options
Falagas, M. E., Rafailidis, P. I., & Matthaiou, D. K. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.05.002 · Cited by 298
Self-citationHistory of antimicrobial drug discovery: Major classes and health impact
Aminov, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.001 · Cited by 296
Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy
Trotman, R. L., Williamson, J. C., Shoemaker, D. M., & Salzer, W. L. (2005) · Clinical Infectious Diseases · doi:10.1086/444500 · Cited by 292
Falagas, M. E., & Karageorgopoulos, D. E. (2008) · Clinical Infectious Diseases · doi:10.1086/528867 · Cited by 290
Self-citationMobilized colistin resistance (mcr) genes from 1 to 10: a comprehensive review
Hussein, N. H., AL-Kadmy, I. M. S., Taha, B. M., & Hussein, J. D. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06307-y · Cited by 290
Antimicrobial peptides: new hope in the war against multidrug resistance
Mwangi, J., Hao, X., Lai, R., & Zhang, Z.-Y. (2019) · Zool. Res. · doi:10.24272/j.issn.2095-8137.2019.062 · Cited by 289
Multidrug-Resistant Gram-Negative Infections: What are the Treatment Options?
Giamarellou, H., & Poulakou, G. (2009) · Drugs · doi:10.2165/11315690-000000000-00000 · Cited by 288
A review on colistin nephrotoxicity
Ordooei Javan, A., Shokouhi, S., & Sahraei, Z. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1865-4 · Cited by 287
Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance
Burmeister, A. R., Fortier, A., Roush, C., Lessing, A. J., Bender, R. G., Barahman, R., Grant, R., Chan, B. K., & Turner, P. E. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919888117 · Cited by 287
Colistin Update on Its Mechanism of Action and Resistance, Present and Future Challenges
Andrade, F. F., Silva, D., Rodrigues, A., & Pina-Vaz, C. (2020) · Microorganisms · doi:10.3390/microorganisms8111716 · Cited by 284
A new strategy to fight antimicrobial resistance: the revival of old antibiotics
Cassir, N., Rolain, J.-M., & Brouqui, P. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00551 · Cited by 280
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Current Update on Intrinsic and Acquired Colistin Resistance Mechanisms in Bacteria
Gogry, F. A., Siddiqui, M. T., Sultan, I., & Haq, Q. M. R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.677720 · Cited by 265
Carvacrol and thymol: strong antimicrobial agents against resistant isolates
Memar, M. Y., Raei, P., Alizadeh, N., Akbari Aghdam, M., & Kafil, H. S. (2017) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000100 · Cited by 264
Epidemiology of mobile colistin resistance genes mcr-1 to mcr-9
Ling, Z., Yin, W., Shen, Z., Wang, Y., Shen, J., & Walsh, T. R. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa205 · Cited by 262
Colistin: new lessons on an old antibiotic
Yahav, D., Farbman, L., Leibovici, L., & Paul, M. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03734.x · Cited by 259
Acinetobacter baumannii: a universal threat to public health?
Giamarellou, H., Antoniadou, A., & Kanellakopoulou, K. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.02.013 · Cited by 258
Huang, C., Song, P., Fan, P., Hou, C., Thacker, P., & Ma, X. (2015) · The Journal of Nutrition · doi:10.3945/jn.115.217406 · Cited by 256
Rhouma, M., Beaudry, F., Thériault, W., & Letellier, A. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01789 · Cited by 253
Lo-Ten-Foe, J. R., de Smet, A. M. G. A., Diederen, B. M. W., Kluytmans, J. A. J. W., & van Keulen, P. H. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01406-06 · Cited by 242
Manohar, P., Shanthini, T., Ayyanar, R., Bozdogan, B., Wilson, A., Tamhankar, A. J., Nachimuthu, R., & Lopes, B. S. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000508 · Cited by 104
Meneguetti, B. T., Machado, L. D. S., Oshiro, K. G. N., Nogueira, M. L., Carvalho, C. M. E., & Franco, O. L. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02136 · Cited by 77
Isa, K., Oka, K., Beauchamp, N., Sato, M., Wada, K., Ohtani, K., Nakanishi, S., McCartney, E., Tanaka, M., Shimizu, T., et al. (2016) · Human & Experimental Toxicology · doi:10.1177/0960327115607372 · Cited by 52
Rossetti, P., Trollmann, M. F. W., Wichmann, C., Gutsmann, T., Eggeling, C., & Böckmann, R. A. (2026) · Small · doi:10.1002/smll.202411476 · Cited by 25
Metadata
- Authors
- Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-05-01
- Volume
- 40
- Issue
- 9
- Pages
- 1333-1341
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2117795567
- Cited by
- 1,744
- References
- 36
- FWCI
- 22.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.